8-K: OrthoPediatrics Q3 2025 Revenue Up 12%, Adjusted EBITDA Jumps 56%

OrthoPediatrics Corp. reported a 12% year-over-year revenue increase to $61.2 million and a 56% rise in Adjusted EBITDA to $6.2 million for Q3 2025, despite a GAAP diluted loss per share of $(0.50).

Summary

• Total revenue for the third quarter of 2025 reached a record high of $61.2 million, marking a 12% increase from $54.6 million in Q3 2024.
• Adjusted EBITDA increased by 56% year-over-year to $6.2 million in Q3 2025, compared to $4.0 million in Q3 2024.
• GAAP diluted loss per share was $(0.50) in Q3 2025, worsening from $(0.34) in Q3 2024.
• Non-GAAP diluted loss per share was $(0.24) in Q3 2025, worsening from $(0.18) in Q3 2024.
• Free cash flow usage improved significantly by $8.2 million, totaling $3.4 million in Q3 2025 compared to $11.6 million in Q3 2024.
• The company helped over 37,000 children in Q3 2025 and approximately 1.3 million children to date.
• Full year 2025 revenue guidance was reiterated in the range of $233.5 million to $234.5 million, representing 14% to 15% growth over 2024.
• Full year 2025 Adjusted EBITDA guidance was reiterated at $15.0 million to $17.0 million.
• Completed first procedures with the VerteGlide Spinal Growth Guidance System and received FDA approval for the 3P Pediatric Plating Platform Small-Mini System.

Sentiment

Score: 6

Explanation: The company demonstrated strong revenue and Adjusted EBITDA growth, alongside positive product developments and improved free cash flow. However, these positives are tempered by increased GAAP and non-GAAP net losses, significant non-cash charges (intangible asset impairment, restructuring), and underperformance in specific segments. The reiterated full-year guidance provides some stability, but the path to sustained profitability still involves substantial expenses and operational adjustments.

Positives

• Total revenue increased 12% year-over-year to a record high of $61.2 million.
• Adjusted EBITDA increased significantly by 56% year-over-year to $6.2 million.
• Domestic revenue grew 14% and international revenue grew 6% in the quarter.
• Worldwide Trauma & Deformity revenue increased 17% year-over-year.
• Gross profit margin improved to 74% in Q3 2025 from 73% in Q3 2024, driven by a favorable product sales mix.
• Free cash flow usage improved by $8.2 million, indicating better cash management.
• Successfully completed first procedures with the VerteGlide Spinal Growth Guidance System.
• Received FDA approval for the 3P Pediatric Plating Platform Small-Mini System, expanding the product portfolio.
• Full year 2025 revenue and Adjusted EBITDA guidance were reiterated, signaling confidence in achieving annual targets.

Negatives

• GAAP diluted loss per share worsened to $(0.50) in Q3 2025 from $(0.34) in Q3 2024.
• Non-GAAP diluted loss per share worsened to $(0.24) in Q3 2025 from $(0.18) in Q3 2024.
• Net loss for Q3 2025 increased to $11.8 million compared to $7.9 million in Q3 2024.
• 7D capital sales and performance in Latin and South America did not meet expectations.
• Sports Medicine/Other revenue decreased 35% to $0.8 million.
• Total operating expenses increased 20% to $54.7 million, driven by restructuring charges, intangible asset impairment, and increased non-cash stock compensation.
• Recorded $2.3 million in intangible asset impairment related to ApiFix, Telos, and Medtech trademark assets and a Telos customer relationship.
• Incurred $2.3 million in restructuring charges, including a $1.9 million goodwill write-off related to the exit of the Telos entity.
• Cash, cash equivalents, short-term investments, and restricted cash decreased to $59.8 million as of September 30, 2025, from $70.8 million at December 31, 2024.

Risks

• Risks related to widespread health emergencies, such as COVID-19 and respiratory syncytial virus, and their potential impact on product demand and the company's ability to respond to related challenges.
• General risks, uncertainties, and factors outlined in OrthoPediatrics' Annual Report on Form 10-K filed with the SEC on March 5, 2025, and subsequent SEC reports.

Future Outlook

The company's full year 2025 revenue guidance remains in the range of $233.5 million to $234.5 million, indicating 14% to 15% growth over 2024. Adjusted EBITDA guidance for the full year is reiterated at $15.0 million to $17.0 million. Management is focused on executing strategic initiatives, including scaling OPSB, leveraging prior set deployments, and introducing innovative new products, with the goal of driving revenue growth, increasing adjusted EBITDA, and meaningfully reducing cash burn to achieve free cash flow break-even in 2026.

Management Comments

• "We are proud of the company's overall third quarter performance."
• "Although, 7D and Latin and South America did not meet our expectations, OrthoPediatrics continues to lead the pediatric orthopedic market by delivering comprehensive solutions that advance the care of children worldwide."
• "Our focus remains on strong execution of our strategic initiatives including scaling OPSB, leveraging prior set deployments, and introducing innovative new products."
• "We are confident this approach will drive revenue growth, increase adjusted EBITDA, and meaningfully reduce cash burn as we move toward achieving free cash flow break-even in 2026."
• "Ultimately, we believe our strategy positions OrthoPediatrics to help more children than ever before."

Industry Context

OrthoPediatrics operates exclusively in the specialized and growing pediatric orthopedics market. The company's strategy of focusing on comprehensive solutions, scaling its OrthoPediatrics Specialty Bracing (OPSB) segment, leveraging existing product deployments, and continuous innovation with new product introductions like VerteGlide and the 3P Pediatric Plating Platform, aims to reinforce its leadership position. The mixed financial results, with strong growth in core segments like Trauma & Deformity, but underperformance in areas like 7D capital sales and certain international markets, reflect the dynamic and sometimes challenging nature of specialized medical device sectors.

Stakeholder Impact

• Shareholders: Mixed impact. Strong revenue and Adjusted EBITDA growth are positive, but increased net losses and non-cash charges may raise concerns. Reiterated full-year guidance provides some confidence in future performance.
• Customers (Children/Patients): Positive impact through helping over 37,000 children in Q3 and 1.3 million to date, along with new product approvals (3P Pediatric Plating) and successful first procedures (VerteGlide Spinal Growth Guidance System).
• Employees: Impacted by the global restructuring plan initiated in Q4 2024, which aims to improve operational efficiency and reduce staffing.
• Creditors: Total liabilities increased, including a significant increase in long-term loans, which may be a point of interest for creditors.

Next Steps

• OrthoPediatrics will host a conference call on Tuesday, October 28, 2025, at 4:30 p.m. ET to discuss the results.
• Continue strong execution of strategic initiatives, including scaling OPSB, leveraging prior set deployments, and introducing innovative new products.
• Work towards achieving free cash flow break-even in 2026.

Key Dates

Recommendation

While OrthoPediatrics demonstrated strong revenue growth and a significant increase in Adjusted EBITDA, the substantial rise in net loss and diluted loss per share, driven by intangible asset impairments and restructuring charges, warrants caution. The company's reiterated full-year guidance and improved free cash flow usage are positive signals, indicating a path towards future profitability (free cash flow break-even in 2026). However, the underperformance in 7D capital sales and Latin/South America, coupled with ongoing operational expenses and non-cash charges, suggests that the company is still navigating a complex growth phase. A 'hold' recommendation allows investors to monitor the execution of strategic initiatives and the progress towards reducing cash burn and achieving profitability without taking on additional risk at this juncture.

Keywords

Pediatric orthopedics, Medical devices, Trauma & Deformity, Scoliosis, Sports Medicine, 7D Surgical, VerteGlide, ApiFix, 3P Pediatric Plating, FDA approval, Earnings, Financial results, Q3 2025, OrthoPediatrics, KIDS